| Literature DB >> 26341803 |
Jean-Yves Lazennec1, Alain Aaron2, Olivier Ricart3, Jean Patrick Rakover4.
Abstract
The viscoelastic cervical disk prosthesis ESP is an innovative one-piece deformable but cohesive interbody spacer. It is an evolution of the LP ESP lumbar disk implanted since 2006. CP ESP provides six full degrees of freedom about the three axes including shock absorbtion. The prosthesis geometry allows limited rotation and translation with resistance to motion (elastic return property) aimed at avoiding overload of the posterior facets. The rotation center can vary freely during motion. The concept of the ESP prosthesis is fundamentally different from that of the devices currently used in the cervical spine. The originality of the concept of the ESP® prosthesis led to innovative and intense testing to validate the adhesion of the viscoelastic component of the disk on the titanium endplates and to assess the mechanical properties of the PCU cushion. The preliminary clinical and radiological results with 2-year follow-up are encouraging for pain, function and kinematic behavior (range of motion and evolution of the mean centers of rotation). In this series, we did not observe device-related specific complications, misalignment, instability or ossifications. Additional studies and longer patient follow-up are needed to assess long-term reliability of this innovative implant.Entities:
Keywords: Artificial disk; CP ESP; Cervical disk prosthesis; Cervical spine mobility; Degenerative cervical disk; Rotation center; Viscoelastic disk replacement
Mesh:
Substances:
Year: 2015 PMID: 26341803 PMCID: PMC4705139 DOI: 10.1007/s00590-015-1695-1
Source DB: PubMed Journal: Eur J Orthop Surg Traumatol ISSN: 1633-8065
Fig. 1Radiological images with CP ESP disk implant
Fig. 2Description of the implant
Comparison of the characteristics of the CP ESP implants and normal cervical disk as reported in the literature
| CP ESP | Natural disk | |
|---|---|---|
| Stiffness for compression | 733 N/mm | 492 N/mm |
| Moment for extension | 0.03 Nm/1° | 0.5 Nm/1° |
| Moment for flexion | 0.03 Nm/1° | 0.03 Nm/1° |
| Moment for lateral bending | 0.05 Nm/1° | 0.9 Nm/1° |
| Moment for rotation | 0.24 Nm/1° | 0.8 Nm/1° |
Fig. 3Description of the cycle testing according to ISO 18192 Norm
Fig. 4Different configurations have been tested regarding the location of the rotation centers to address the worst case scenarios during the tests
Literature summary of biomechanical simulations for wear
| References | Device | Simulation | Mass loss | Height loss | Volume loss |
|---|---|---|---|---|---|
| Anderson et al. [ | Bryan | 6 disks: 10 million cycles; 150 N force flexion/extension, lateral bending and axial rotation in 37 °C calf serum sample; bending + 10 million cycles rotation at 4 Hz; 4 disks: tested until and plate to endplate contact | 1.75 % (after 20 million cycles in 6 disks) | 0.48 % (after 20 million cycles in 6 disks) | 0.57 mm3/million cycles |
| Anderson et al. [ | Prestige | 10 million cycles of 148 N flexion/extension, 5 million cycles of 49 N lateral bending and 5 million cycles of 49 N axial rotation at 2 Hz in 37 °C calf serum sample; number of disks tested not reported | NR | NR | 0.18 mm3/million cycles (0, 19 % loss after 20 million cycles) |
| FDA [ | ProDisc C | 10 million cycles of 150 N flexion/extension, lateral bending and axial rotation at 1 Hz in 37 °C calf serum sample; debris sampled every million cycles | 2.59 mg/million cycles | NR | NR |
| Grupp et al. [ | Active C | 6 disks tested with a ISO 18192-1:2008 (E) | 1.0 mg/million cycles | 0.03 mg/million cycles for polymer inlay | 1.0 mm3/million cycles |
| FDA [ | PCM | 5 disks tested under Draft ASTM F243-05 conditions (±10° fully reversing lateral bending, ±6° fully reversing axial) | Average cumulative wear at 10 million cycles was 71.22 ± 17.56 mg. Wear rate 0.042 mg/million cycles between 3 and 10 million cycles | NR | NR |
| FDA [ | Secure-C | 150 N constant compressive load for 10 million cycles. | Stage 1: 2.57 mg ± 1.21 mg per million cycles | NR | NR |
| FDA [ | Mobi C | 6 disks: 10 million cycles; frequency of 1 Hz | 1.456 ± 0.075 mg/million cycles | NR | NR |
| FDA [ | Prestige LP | Stage 1: 6 disks tested in accordance with ASTM 2423 (lateral bending coupled with axial rotation followed by flexion/extension) | NR | NR | Stage 1: 0.35 ± 0.03 mm3/million cycles |
| CP ESP | 3-Axis motion simulator according to the ISA 18192 Norm | Mean variation of weight 0.8 mg for 10 million cycles | Loss of height ranged from 0.02 to 0.12 mm after 10 million cycles |
NR indicates not reported
Biocompatibility tests for CP ESP
| Tests | Results | Standard |
|---|---|---|
| Mutagenicity | Nonmutagenic | OECD N° 471 |
| Chronic toxicity | Macroscopic reaction nonsignificant | ISO 10993-1 |
| Hemolysis | Nonhemolytic | ISO 10993-4 |
| Humoral immunological study | No humoral (serological) immune response | OECD N° 407 |
| ESP pyrogenicity | Nonpyrogenic | ISO 10993-11 |
| Sensitization | No dermal sensitization | ISO 10993-10 |
| Acute systemic toxicity | No significant systemic toxicity | ISO 10993-11 |
| ESP implantation | Macroscopic reaction not significant | ISO 10993-6 |
| Intracutaneous toxicity | No significant toxicity or irritation | ISO 10993-10 |
| Carcinogenicity | Noncarcinogenic | ISO 10993-3 |
Description of the pilot study
| Operated levels | Patients | CP ESP implants | |
|---|---|---|---|
| 1 level | C3C4 | 1 | 53 (74 % of the implants) |
| C4C5 | 4 | ||
| C5C6 | 26 | ||
| C6C7 | 20 | ||
| C7D1 | 2 | ||
| 2 levels | C4C5/C5C6 | 2 | 18 (26 % of the implants) |
| C5C6/C6C7 | 6 | ||
| C6C7/C7D1 | 1 | ||
| 71 implants |
Clinical outcomes of the preliminary study
| Mean ± SD | Pre-op | 3 Months | 6 Months | 12 Months |
|---|---|---|---|---|
| ( | ||||
| VAS neck (/10) | 6 | 2.65 | 1.74 | 2.65 |
| VAS arm (/10) | 6.3 | 2.7 | 1.8 | 2.4 |
| NDI (%) | 56 ± 16 | 32.7 ± 17 | 22.1 ± 16 | 24 ± 17 |
| NDI points | 27.4 ± 8.8 | 16.2 ± 8.6 | 10.9 ± 7.9 | 11.9 ± 8.5 |
| SF-36 PCS score | 31 | 48 | 61 | 56 |
| SF-36 MCS score | 32 | 50 | 63 | 62 |
Evolution of the ROM of the implanted and adjacent levels
| Degrees (°) | 3 Months | 6 Months | 12 Months |
|---|---|---|---|
| ROM of the instrumented level | 6.8 ± 4.1 | 10.3 ± 5.0 | 8.4 ± 4.3 |
| ROM of the upper adjacent level | 9.7 ± 4.9 | 11.7 ± 5.5 | 12.9 ± 6.8 |
| ROM of the lower adjacent level | 6 ± 4.1 | 10 ± 5.0 | 9.4 ± 5.7 |
Fig. 5Mean centers of rotation (MCR) at the instrumented and at the upper and lower adjacent levels measured for flexion/extension using Spineview® software; we can observe the adaptation of the implant including a translation for flexion
Clinical and radiological outcomes after 2-year follow-up
| Mean ± SD | 24 Months |
|---|---|
| VAS neck (/10) | 2.9 |
| VAS arm (/10) | 1.6 |
| NDI (%) | 19 ± 17 |
| NDI points | 9.3 ± 8 |
| SF-36 PCS score | 64.2 |
| SF-36 MCS score | 68.6 |
| ROM of the instrumented level | 10.7° ± 4.2° |
| ROM of the upper adjacent level | 13.8° ± 6.5° |
| ROM of the lower adjacent level | 11.1° ± 8.2° |
Fig. 6a–f Mean centers of rotation (MCR) and mobility at the instrumented and at the upper and lower adjacent levels in a patient with global cervical kyphosis: adaptation during the follow-up from 3 to 24 months